Demographic, clinical, and serological characteristics of the study groups.
| RA Group | Non-RA Group (n = 83) | ||||
|---|---|---|---|---|---|
| SLE (n = 38) | pSS (n = 17) | OA (n = 11) | HC (n = 17) | ||
| Age, yrs median (range) | 53.8 (26–76) | 42 (24–65) | 58 (21–82) | 65.5 (45–85) | 51 (25–71) |
| Male:female | 1:5 | 1:10 | 1:17 | 3:5 | 1:10 |
| DAS-28, mean (SD) | 4.7 (1.3) | ||||
| VAS, mean (SD) | 43.5 (26.4) | ||||
| ESR; mm/h, mean (SD) | 42.2 (24.8) | ||||
| CRP, mg/l, mean (SD) | 12.0 (13.5) | ||||
| RF positivity, n (%) | 61 (65.6) | 1 (2.6) | 4 (23.5) | 1 (9.1) | 1 (5.9) |
| Anti-CCP2 positivity, n (%) | 54 (58.1) | 1 (2.6) | 0 | 0 | 0 |
| Anti-CCP3 positivity, n (%) | 57 (61.3) | 1 (2.6) | 0 | 0 | 1 (5.9) |
| AxSYM anti-CCP positivity, n (%) | 75 (80.7) | 6 (15.8) | 5 (29.4) | 0 | 2 (11.8) |
| Anti-MCV positivity, n (%) | 45 (48.4) | 5 (13.2) | 2 (11.8) | 0 | 0 |
DAS-28: Disease Activity Score-28; VAS: visual analog scale; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; pSS: primary Sjögren’s syndrome; HC: healthy controls; RF: rheumatoid factor; CCP: cyclic citrullinated peptide; MCV: mutated citrullinated vimentin.